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Antifertility Effects and Dominant Lethal
Assays for Mutagenic Effects of DEHP
by John Autian*
Results of past animal studies have indicated the antifertility effects of phthalate esters and
additional studies have suggested the potential mutagenic effects at very high doses. A toxicity
study in mice has also been conducted in which chronic LD50 values were calculated for a group
ofphthalate esters. For DEHP, for example, the acute LD50 was 38.35 ml/kg, but after 10 weeks
thevalue fell to 1.37ml/kg, suggesting thatthe esterwas producing acumulativetoxicity. A more
recent study explored the possibility that DEHP might be a cumulative toxic agent even at lower
doses in regard to antifertility and mutagenic effects in mice. Preliminary results indicated that
antifertility effects occurred with as little as three subcutaneous doses of 1 ml/kg each.
Calculations of mutagenic index revealed a dose-dependent effect but no stoichiometric
relationship was established.
Introduction
In the United States, concern forpotential health
threats from the leaching of phthalate esters used
as plasticizers in poly(vinyl chloride) items such as
blood bags and tubings dates back to a report
published in 1967 by Guess et al. (1). Their studies
on blood bags containing ACD solution revealed
that the plasticizers, as well as degradation prod-
ucts of the ester, were released to the solution.
While the quantity of the released chemicals was
extremely small, the question was raised for the
safety of these products when administered to ill
and debilitated patients. Although notice was taken
of this report, neither government nor industry
took steps to correct the "contaminated" ACD
solution or blood products placed in these PVC
bags. Their past history of use and their apparent
safetymitigated the need formaking changes inthe
plastic though industry had begun to initiate stud-
ies to help improve the PVC formula.
Publication of research by Jaeger and Rubin (2)
in 1970, however, resurrected the plastic's safety
into abroaderdomain. Theseinvestigators reported
the detection of residual amounts of phthalate
esters in anumberoforgans and tissues ofdeceased
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patients who had a recent history ofblood therapy
from PVC blood bags. Fromthatdate, considerable
research has taken place on the toxicology of the
various phthalates, in particular, di(2-ethylhexyl)
phthalate (DEHP). Two major phthalate confer-
ences have also been held; one in 1973 and the
present one. Since the initial review ofthe toxicol-
ogy of phthalate esters by Autian in 1973 (3)
additional reviews have appeared in literature.
Yet, after a decade and a half, no resolution ofthe
safety issue has occurred, and the volume of
medical devices used in medical applications has
increased considerably since that time. The recent
findings that DEHP has induced tumors in both
rats and mice may become the pivotal point for a
regulatory agency such as FDA to ban PVC (with
phthalate esters)fromspecificuses(NationalCancer
Institute, unpublished report).
It is now well established that DEHP and most
other diesters of phthalic acid have been found to
have a very low order of acute toxicity. Chronic
animal studies performed in the 1950s and 1960s
(with the exception of the very recent cancer
studies) also suggest that low levels of phthalate
esters taken in feed on a daily basis have no
significant toxicologic consequence, even though
there was some indication of liver involvement at
the higher dose levels.
A more recent study on chronic toxicity by
Lawrence et al. (4) permitted the calculations of116
chronic LD50 for a group of phthalate esters. In
these experiments, a group of mice was injected
IP with a series ofdoses five days per week. At the
end ofeachweek, an apparent LD50 was calculated.
This procedure was continued until the apparent
LD50remained constantforthreeconsecutiveweeks
with aminimum of10 weeks treatment. Table 1 is a
summary ofthis study and includes the acute LD50,
the chronic LD50 and a cumulative toxicity factor
(acute chronic). It will be noted that there is a
dramatic cumulative factor for both the di-n-octyl
and di(2-ethylhexyl) phthalates as compared to the
other phthalates. This suggests that, under the
experimental conditions, these dioctyl and di(2-
ethylhexyl) phthalates do have a marked cumula-
tive effect. For example, DEHP has an acute LD50
of38.35 ml/kg. Over a 10-week period this value is
reduced to 1.37 mli/kg. Presently there is no infor-
mation which explains this type of response, but it
may be that the metabolites ofthe two esters play a
much greater role in the mechanism of action than
for the lower molecular diesters; this remains
conjecture at this time. It might, however, be
pointed out that Kevy et al. (5) did find the
presence of DEHP (or its metabolites) in livers of
monkeys manymonths afterthe last administration
of the compound. Most investigators, however, do
not support the cumulative theory for DEHP based
upon their studies in rodents.
Singh et al. (6) studied the teratogenic effects of
eight phthalate esters in rats and noted that all
compounds, to various degrees, induced birth abnor-
malities and fetal deaths. Esters included the
following:dimethyl, dimethoxyethyl, diethyl, dibutyl,
diisobutyl, butyl carobutoxymethyl, dioctyl and
di(2-ethylhexyl) phthalates. Groupsofanimals were
administered the various esters by IP injections on
days 5, 10, and 15 of gestation at several dose
levels. The most widely used phthalate, di(2-ethyl-
hexyl) phthalate (DEHP), was administered at two
dose levels, 5 ml and 10 ml/kg, but fetal abnormali-
ties were noted only at the higher dose level.
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Since PVC blood bags generally contain DEHP
as the plasticizer, a study was conducted by
Lewandowski et al. (7) in which two types of PVC
bloodbagmaterials were extracted with ratplasma
to give a concentration of DEHP approximately
equivalent to the dose a human weighing 60 kg
could receive during an exchange transfusion of
21-day-old blood. Several dose levels were used,
ranging from 1.4 mg/kg per day to 5.3 mg/kg per
day. Thevariousdoses wereadministeredto groups
of pregnant rats IV from day 6 through day 15 of
gestation. No teratogenic effects or adverse conse-
quences were noted in any of the experimental
animals as compared to control groups not receiv-
ing the DEHP, supporting the contention of the
authors that blood products stored in PVC would
not present a teratogenic risk to pregnant humans.
In another study by Singh and associates (8),
DEHPanddimethoxyethylphthalate(DMEP) were
administered by IP injection to adult male mice,
and subsequently these mice, individually, were
mated to groups of two adult virgin females. This
sequence with new females was repeated weekly
for 12 weeks. Between days 13 and 17 ofgestation,
the pregnant mice were sacrificed and the uterine
horns and ovaries exposed. Corpora lutea, total
numberofimplantations, earlyandlatefetaldeaths,
pre-implantation losses and viable fetuses (litter
size) were determined. Interpretations ofthe data
suggested to the authors that the two esters had
the potential to act as mutagenic agents as well as
to suppress fertility.
Recent Preliminary Studies on
Antifertility and Mutagenic Effects
of DEHP in Mice
As has alreadybeendescribed, DEHP appears to
have an antifertility effect when male mice are first
treated with the compound and then subsequently
mated with virgin female mice. This response in
Table 1. Chronic toxicity of phthalate esters in mice (IP).8
Acute LD50 Chronic LD50 Cumulative toxicity factor
Ester (ml/kg) (ml/kg) (acute/chronic)
Dimethyl 3.35 1.18 2.84
Diethyl 2.87 1.39 2.06
Di-n-butyl 3.41 0.85 4.01
Diisobutyl 3.84 1.87 2.05
Di-n-octyl 67.18 3.09 21.74
Di-2-ethylhexyl 38.35 1.37 27.99
Butyl carobutoxymethyl 6.27 3.04 2.06
Bis(2-methoxyethyl) 3.57 1.41 2.53
aFrom Lawrence et al. (4). Infornation summarized from Table 3 in Lawrence's article. Forthe chronic study, groups ofmice were
injected IP with a series ofdoses five days per week. At the end ofeach week, an apparent LD50 was calculated. This procedure was
continued until the apparent LD50 remained constant for three consecutive weeks with a minimum of 10 weeks treatment.ANTIFERTILITY AND MUTAGENIC EFFECTS OF DEHP
general is dose-related. Results from dominant
lethal assays also suggest that at high doses DEHP
might be acting as a mutagenic agent.
The possibility that DEHP might be a cumulative
toxic agent, even at lower doses, prompted our
laboratories to initiate several preliminary experi-
ments to clarify whether a possible cumulative
effect can impose both an antifertility effect and
mutagenic effects during an 8-week period.
Experimental
In the first series ofexperiments, male mice were
injected with DEHP subcutaneously on days 1, 5
and 10 at dose levels ranging from 1.0 ml/kg to 100
ml/kg. Seven or more mice were used for each dose
level. Normal virgin females were mated individu-
allywith eachtreatedand controlmale mouse onday
21 following the first injection. Animals of the two
sexes were kept together for four consecutive days
and females examined every day forthe presence of
vaginal plugs as an indication ofmatings. Detection
of the vaginal plug was taken as the first day of
gestation. Bred females were sacrificed on days
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12-13 of gestation, and uterine horns and ovaries
were exposed surgically to determine the number
of corpora lutea, implantations, preimplantation
losses, early fetal deaths and viable fetuses.
A second series of experiments was also con-
ducted essentially followingthe previously described
procedure. Groups of 10 male mice were treated
with DEHP subcutaneously on days 1, 5 and 10 at
the following dose levels: 1 ml/kg, 2 ml/kg, 5 ml/kg
and 10 ml/kg. A group of untreated mice was used
as control. Each male mouse was mated with a
fresh virgin female 24 hr after the treatment,
followed by a change of females every fifth day up
to 21 days and then every week up to 8 weeks. All
pregnant females were sacrificed as previously and
the corpora lutea, implantations, preimplantation
losses, earlyfetaldeathsandviablefetusesrecorded.
Results
Table 2 summarizes the number of pregnancies
occurring for each dose administered, as well as the
number of corpora lutea, implants, preimplantation
losses, early fetal deaths and live fetuses. It will be
Table 2. Antifertility and mutagenic trends from injection (SC) ofDEHP in groups ofmale mice at days 1, 5 and 10 and mated
with normal females on day 21.8
Incidence of Number of Preimplan- Early fetal Number of
Group pregnancy corpora lutea Implant tation losses deaths live fetuses
Saline control 14/16 (88) (87.5%) 12.62 10.43 2.19 0.37 10.06
DEHP-treated
1 mi/kg 5/8 (68) (62.5%) 12.87 7.62 5.25 2.75 4.87
2 ml/kg 3/8 (38) (37.5%) 14.00 5.37 8.63 0.87 4.50
5 mI/kg 3/8 (38) (37.5%) 15.12 4.87 10.25 1.00 3.87
10 mi/kg 3/8 (38) (37.5%) 14.50 4.75 9.75 1.62 3.13
15 ml/kg 2/8 (25) 15.52 3.50 12.02 1.12 2.38
20 ml/kg 0/8 (0) 13.87 b 13.87 b b
40 mi/kg 1/7 (14) (14/2%) 14.14 1.85 12.29 0.00 1.85
60 mi/kg 0/8 (0) 11.25 b 11.25 b b
80 ml/kg 1/9 (11) (11.1%) 16.33 1.33 15.00 0.00 1.33
100 ml/kg 0/8 (0) 18.44 __b 18.44 __b _b
'Data are expressed as mean value per animal for each group.
bNo pregnancies in this group.
Table 3. Mutagenic index (early fetal deaths/total implants per pregnancy) x 100.
DEHP-treated
Time ofmating Control 1 ml/kg 2 ml/kg 5 mi/kg 10 ml/kg
Day 2 0.43 1.81 5.0 2.99 3.58
Days 6 0.34 0.52 0.43 1.42 0.66
Days 11 0.66 0.86 2.14 2.64 3.51
Days 16 0.36 2.02 2.50 2.08 1.60
Days 21 0.19 0.80 1.60 2.47 4.44
Weeks 4 0.38 1.40 1.22 1.15 2.69
Weeks 5 0.45 1.82 3.33 1.49 3.48
Weeks 6 0.30 0.76 3.05 2.86 3.33
Weeks 7 0.18 2.35 1.75 1.23 1.31
Weeks 8 0.60 1.17 2.20 1.55 1.68118 J. AUTIAN
noted that an antifertility effect is apparent even at
the 1 ml/kg dose level, though statistical analysis
was not performed on these data. The trend of
antifertility increases as the dose administered to
the male mice increases. Increased early fetal
deaths and preimplantation losses also can be noted
with the treated animals, the trend generally
increasing as the dose administered is increased.
Again, the data are suggestive and not definitive
under the experimental conditions employed.
Data generated from the second series of exper-
iments, in which treated male mice were mated
with virgin female mice at different intervals (from
day 2 to 8 weeks), were used to calculate the
mutagenic index (early fetal deaths/total implants
x 100). These values are shown in Table 3. A
review of the table indicates that the mutagenic
index increases as the dose is increased, although
again it cannot be said if these increases are
significantly different from the control group. The
trend, however, is clear; the mutagenic index is
higher for treated animals on the average than for
the control groups at any of the time periods.
Discussion
Previous studies in this laboratory demonstrated
that at high doses (IP), the phthalate esters could
act as teratogenic and antifertility agents (6).
Results from a dominant lethal assay also sug-
gested that the esters might have mutagenic activ-
ity (8). Since DEHP was found to exert a cumula-
tive toxicity effect in mice, these experiments were
undertaken to determine antifertility and muta-
genic effects ofrepeated injection ofDEHP in mice
at various dose levels.
As suggested in Table2, antifertility effects were
notedwith as little as three subcutaneous doses of1
ml/kg each. Calculations of mutagenic index (early
fetal deaths/total implants per pregnancy x 100)
have been listed in Table 3 for the various dose
levels (1, 2, 5 and 10 ml/kg) over an eight-week
period. Even though a dose-dependent effect is
apparent, no stoichiometric relationship- has been
established.
Expression of mutagenic index in terms of per
pregnancy excludes any possible antifertility effect
from DEHP, although the antifertility effects
observed in this study may also be a consequence of
the mutagenic effects rendering the sperm incapa-
ble offertilizingthe ovum or forthe fertilized ovum
to develop.
In aparallelstudynotreportedhere, the effectof
lower doses of DEHP on testicular structure and
functiondidnotshowanychangesinhistopathological
organization or macromolecular contents (nucleic
acids and protein) of the tissue, suggesting that
increased fetal deaths are not a consequence of
testicular atrophy. Alterations in the activity of
certain mitochondrial and lysosomal enzymes of
testicular tissue were, however, observed after
treatment with DEHP to account forthe changes in
the functional ability of the reproductive system.
It has always been a point of argument in
selecting doses ofDEHP and/or the route ofadmin-
istration in experimental animals which stimulate
conditions close to that ofhuman exposure or which
provide predictive toxicologic data. A subcutaneous
administration would therefore justify the paren-
teral administration like IV without any possible
direct contact with the organs ofconcern and would
certainly be more practical to assess the toxicity of
DEHP than oral route where most of the effects
would be due to metabolites rather than DEHP
itself. Undoubtedly the doses used in the present
study are much higher than would be expected to
reachthehumansystemthroughbiomedical devices.
However, in view of the marked increase in the
chronic toxicity and evident accumulation ofDEHP
in primates, usage ofhigher doses ofDEHP in such
short term studies may help in indicating possible
risk of mutagenic effects in human beings exposed
to relatively smaller doses over a longer period of
time.
Further studies in fertility and mutagenic effects
ofDEHP and other phthalate esters are continuing
and the results will be reported in subsequent
publications.
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